Assessment of calcium dobesilate in diabetic retinopathy. A double-blind clinical investigation. 1977

I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama

In this double-blind, randomized trial, which lasted for 2 years, the authors investigated the efficacy of calcium dobesilate on diabetic retinopathy. 68 patients (51 on the active substance, 17 on placebo) participated in the study. The statistical analysis of the results indicate that calcium dobesilate acts as a potent angioprotector, capable of preventing both intra and extraretinal hemorrhages. The drug also lowers the incidence of exudate formation and improves visual acuity.

UI MeSH Term Description Entries
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002123 Calcium Dobesilate A drug used to reduce hemorrhage in diabetic retinopathy. Dobesilate Calcium,2,5-Dihydroxybenzenesulfonate,2,5-Dihydroxybenzenesulfonic Acid,Calcium Dobesilate (1:1),Calcium Dobesilate Monoammonium Salt,Calcium Dobesilate Monopotassium Salt,Dexium,Dobica,Doxium,2,5 Dihydroxybenzenesulfonate,2,5 Dihydroxybenzenesulfonic Acid,Calcium, Dobesilate,Dobesilate, Calcium
D002198 Capillary Fragility The susceptibility of CAPILLARIES, under conditions of increased stress, to leakage. Fragility, Capillary
D002199 Capillary Permeability The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement. Microvascular Permeability,Permeability, Capillary,Permeability, Microvascular,Vascular Permeability,Capillary Permeabilities,Microvascular Permeabilities,Permeabilities, Capillary,Permeabilities, Microvascular,Permeabilities, Vascular,Permeability, Vascular,Vascular Permeabilities
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001557 Benzenesulfonates Organic salts and esters of benzenesulfonic acid.
D012166 Retinal Hemorrhage Bleeding from the vessels of the retina. Hemorrhage, Retinal,Retinal Hemorrhages

Related Publications

I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
December 2006, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
September 1974, Revue medicale de Liege,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
September 1976, Current therapeutic research, clinical and experimental,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
January 1969, Bulletins et memoires de la Societe francaise d'ophtalmologie,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
January 2005, Treatments in endocrinology,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
January 1985, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
June 1998, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
June 1976, Klinika oczna,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
January 1981, Vestnik oftalmologii,
I Salama Benarroch, and H Nano, and H Pérez, and F Elizalde, and H Bisceglia, and A Salama
January 1980, VASA. Zeitschrift fur Gefasskrankheiten,
Copied contents to your clipboard!